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Abstract
Introduction: Preterm birth is a major contributor to neonatal morbidity and mortality and its rate has been increasing over
the past two decades. Antidepressant medication use during pregnancy has also been rising, with rates up to 7.5% in the
US. The objective was to systematically review the literature to determine the strength of the available evidence relating to
a possible association between antidepressant use during pregnancy and preterm birth.
Methods: We conducted a computerized search in PUBMED, MEDLINE and PsycINFO through September 2012,
supplemented with a manual search of reference lists, to identify original published research on preterm birth rates in
women taking antidepressants during pregnancy. Data were independently extracted by two reviewers, and absolute and
relative risks abstracted or calculated. Our a priori design was to group studies by level of confounding adjustment and by
timing of antidepressant use during pregnancy; we used random-effects models to calculate summary measures of effect.
Results: Forty-one studies met inclusion criteria. Pooled adjusted odds ratios (95% CI) were 1.53 (1.40–1.66) for
antidepressant use at any time and 1.96 (1.62–2.38) for 3
rd trimester use. Controlling for a diagnosis of depression did not
eliminate the effect. There was no increased risk [1.16 (0.92–1.45)] in studies that identified patients based on 1
st trimester
exposure. Sensitivity analyses demonstrated unmeasured confounding would have to be strong to account for the
observed association.
Discussion: Published evidence is consistent with an increased risk of preterm birth in women taking antidepressants
during the 2
nd and 3
rd trimesters, although the possibility of residual confounding cannot be completely ruled out.
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Introduction
Preterm birth is a major clinical problem throughout the world.
It is the leading cause of infant mortality: approximately 75% of all
perinatal deaths occur among preterm infants [1]. It is also a
major contributor to both short- and long-term morbidity:
surviving infants are at increased risk of health problems ranging
from neurodevelopmental disabilities such as cerebral palsy and
mental retardation to other chronic health problems such as
asthma [2]. Although the risk is highest in very preterm infants (,
32 gestational weeks), it has been well documented that moderate
(32–33 gestational weeks) and mild (34 to 36 gestational weeks)
preterm birth infants are also at increased risk for neonatal and
post-neonatal mortality and morbidity [3–6]. Rates of preterm
birth have been increasing over the past two decades and it is a
major public health concern [7], with costs to society that have
been estimated to be as high as $26.2 billion per year in the US
[7], and £939 million per year in the UK [8]. It has been reported
that two thirds of these costs are incurred for the care of babies
born moderately prematurely [8].
In many developed countries, the use of antidepressant
medications has increased sharply between 1996 and 2005, and
now surpasses antihypertensives as the most commonly prescribed
drug class in ambulatory care [9]. During this same time period,
rates of antidepressant use during pregnancy have increased
approximately 4-fold, with reported rates of up to 3–6% in Europe
[10–12] and up to 8% in the US [13,14].
Numerous studies, of varying size and quality, have examined
the effects of antidepressant medication use on pregnancy
outcomes, including preterm birth. They differ in terms of the
timing of the antidepressant exposure during pregnancy and
adjustment for potential confounding variables, including lifestyle
factors, co-morbidities, and the severity of the underlying
psychiatric illness. The extent to which such differences contribute
to variability in findings remains to be elucidated. The objective of
this review was to determine the strength of the available evidence
relating to a possible association between antidepressant use
during pregnancy and preterm birth, and to assess this relationship
in terms of (1) the timing of the antidepressant use studied, and (2)
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e92778attempts to control for the possible confounding effects of
depression itself.
Methods
To identify all available studies on the topic of antidepressant
medication use during pregnancy and preterm delivery, we
performed a computerized search in PUBMED, MEDLINE,
and PsycINFO using the key words: (‘‘antidepressant*’’ or
‘‘tricyclic antidepressant*’’ or ‘‘selective serotonin reuptake inhib-
itor*’’ or ‘‘serotonin-norepinephrine reuptake inhibitor*’’) and
(‘‘preterm birth*’’ or ‘‘preterm deliver*’’ or ‘‘pregnanc*’’ or
‘‘pregnancy complication*’’). The databases were searched from
their inception through September 12, 2012. Reference lists of
selected articles were also searched to identify additional studies
that reported on preterm births and antidepressant exposure.
Studies were included if they identified a group of pregnant
women exposed to antidepressants at some point during their
pregnancy as well as a comparison group, and reported on
preterm birth rates, irrespective of whether preterm birth was a
pre-specified study endpoint or one of several pregnancy
characteristics reported. No restrictions were imposed on study
size or design.
Once relevant studies were identified, for each study two
investigators with clinical and epidemiologic expertise (ACU,
KFH) independently abstracted preterm birth rates in the group(s)
exposed to antidepressants and in the comparator group(s). When
these were not expressed as percentages in the manuscript, they
were calculated. Relative risks (expressed as odds ratios in all
studies) were also taken directly from the manuscript. Whenever
available, preference was given to relative risks adjusted for
potential confounding variables. When relative risks were not
reported in the manuscript, we estimated the unadjusted odds
ratio and its corresponding 95% confidence limits (Wald method)
based on the available information. When relative risks were only
presented graphically, we contacted the authors to obtain the
corresponding numerical estimates. Types of antidepressants used,
numbers of users and other pertinent exposure information (e.g.,
time and duration), and potential confounders accounted for were
also retrieved. Any discrepancies in data abstraction were resolved
by consensus between the reviewers.
A funnel plot was examined for evidence of publication bias
[15]. Between-study heterogeneity was examined using the
Cochran Q and I
2 tests [16]. We used a random-effects meta-
analysis model to calculate summary measures of effect while
accounting for heterogeneity across studies [17]. Because of the
critical importance of (1) the timing of antidepressant use during
pregnancy, and (2) the potential for confounding by the presence
of depression itself (confounding by indication), we had deter-
mined a priori to group studies by timing of antidepressant
exposure and level of confounding adjustment. We chose this
approach to address the inherent issues of clinical and method-
ological diversity [18]. Finally, we conducted a sensitivity analysis
to identify the strength of the residual confounding that would be
necessary to fully explain the estimated association between
antidepressant medication use and preterm birth [19].
Results
After an initial screen of the 1,477 studies identified through
database searches, we identified 52 studies that met our
predetermined criteria as possibly assessing the association
between antidepressant use during pregnancy and preterm birth
[20–67] [68–71]. Five studies reported on preterm births in
antidepressant-exposed pregnancies but had no comparison
group, and were excluded [20–24]. In five other studies a
comparison was made between patients treated with antidepres-
sants and untreated controls, but preterm birth rates were not
reported [25–29]. One study used the same cohort [67] for which
preterm birth rates had previously been reported [57]. (Figure 1).
Forty-one studies [30–66,68–71], published between 1993 and
2012, were identified that met entry criteria as reporting on
preterm birth rates in a group exposed to antidepressants versus a
control group (Table 1). All were observational cohort studies; not
surprisingly, no randomized controlled trials have been performed
on this topic. Most studies (n=21) were prospective in nature, four
were bi-directional with some women included during pregnancy
and some post-delivery, and the remaining 16 were retrospective
(i.e., participants were identified after delivery). The majority of
the retrospective studies (n=14) used administrative healthcare
utilization databases. Nine studies recruited patients through
Teratogen Information Services, 17 recruited participants from
clinics, physician offices and other referrals, and the remaining 15
studies used population-based electronic healthcare databases
(with and without linkage to birth registries). The studies ranged in
size from 44 to 1,618,255 participants. As expected, the studies
using electronic healthcare databases were much larger (median:
199,547 participants) than those using other approaches (median:
290 participants).
All but one study defined preterm birth as an infant born before
37 weeks’ gestation, in accord with the WHO definition. Maschi
et al considered infants born before 36 weeks of gestation as
premature [48]. Most studies evaluated the association between
selective serotonin-reuptake inhibitors (SSRI) and preterm birth
(n=22), but some also evaluated other antidepressants such as
tricyclic antidepressants (TCA) and serotonin–norepinephrine
reuptake inhibitors (SNRI) (n=17). Two studies evaluated the
effect of a variety of psychotropic medications, including
antidepressants.
Table 2 presents the findings from the heterogeneity tests, along
with the summary effect estimates from the meta-analysis.
Medium to high heterogeneity was found across studies that
adjusted for potential confounding factors (I
2:46 to 85%), but not
across studies that provided unadjusted estimates (I
2,25%). We
conducted a random-effects meta-analysis of the adjusted estimates
given the consistency in the direction of the effects [18].
Unadjusted Estimates
Figure 2 summarizes the results for the 9 studies that did not
account for potential confounding factors, either by design or
because preterm birth rates were not pre-specified study end-
points. The category ‘Early’ includes studies in which women were
known to have taken antidepressants early in pregnancy, typically
in the first trimester. Some of these women continued antidepres-
sant medication use during pregnancy whereas others discontin-
ued. Studies classified under ‘Any time’ are those in which women
were considered exposed irrespective of the specific time during
pregnancy that medication was used, and studies where the timing
was not specified. If multiple exposures were analyzed in a given
study (e.g., estimate for paroxetine and fluoxetine [37]), they have
all been included to ensure completeness of the evidence
presented.
In these unadjusted analyses, the pooled odds ratio for the risk
of preterm birth following antidepressant use in pregnancy was
1.57 (95% CI 1.30–1.90) for early exposure, and 1.44 (1.34–1.56)
for exposure any time during pregnancy (Figure 2, Table 2). With
the exception of two studies [51,52], the unadjusted point
estimates for all other studies suggest that antidepressant
medication use during pregnancy may be associated with an
Antidepressants and Preterm Birth
PLOS ONE | www.plosone.org 2 March 2014 | Volume 9 | Issue 3 | e92778increased risk of preterm delivery, but the effects are estimated
imprecisely in many studies, as evidenced by the width of the 95%
confidence intervals.
Estimates Adjusted for Potential Confounders
The adjusted odds ratios for the 22 studies which accounted for
potential confounding variables are shown in Figure 3. The
potential confounding factors adjusted for varied between studies,
but typically included maternal age, smoking, alcohol use, parity,
and history of prematurity or miscarriage.
In addition to the previously defined ‘Early’ and ‘Any Time’’
categories defining the timing of antidepressant use, Figure 3 also
includes a ‘Late’ category which comprises studies in which women
were known to use antidepressant medications late in pregnancy,
generally in the third trimester. Results suggest an increased risk of
preterm birth for all exposure-outcome combinations, with four
exceptions. Calderon-Margalit and colleagues [30] found an
increased risk for use of SSRIs late in pregnancy (aOR,
95%CI=4.79, 1.66–13.90), but a much weaker association for
exposure at any time (1.21, 0.67–2.21). Toh et al [58] estimated a
positive association for non-SSRI antidepressants (2.23, 1.02–
4.88), but not for SSRIs (1.12, 0.64–1.95). Klieger-Grossman et al
[61] found a positive association for escitalopram (2.21, 0.98–
5.00), but not for all other antidepressants combined (1.12, 0.44–
2.81). Hayes et al [70] observed a positive association and a dose-
response relation with second trimester exposure, but not with first
trimester exposure.
In general, associations appeared stronger for antidepressant use
known to have occurred late in pregnancy (pooled aOR, 95% CI:
1.16, 0.92–1.45 for early exposure; 1.53, 1.40–1.67 for exposure at
any time; and 1.96, 1.62–2.38 for late exposure) (Figure 3,
Table 2).
Estimates Adjusted for Psychiatric Illness
A major concern about the validity of studies assessing the effect
of antidepressant medications on preterm birth is the potential for
confounding by indication. It has been hypothesized that the
underlying depression and its severity, or the behaviors potentially
Figure 1. Study selection flowchart.
doi:10.1371/journal.pone.0092778.g001
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PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92778associated with depression (e.g., smoking, alcohol intake, nutri-
tional changes), rather than antidepressant medication, may
themselves increase the risk of preterm birth [72]. A few studies
tried to address this concern directly by using as a comparator
group women with a diagnosis of depression or other psychiatric
illnesses who did not use antidepressant medications during their
pregnancy, or by adjusting for the presence of a psychiatric
diagnosis (Figure 4). Most of these 11 studies nonetheless found an
increased risk of preterm birth associated with antidepressant
medication use, resulting in a pooled OR of 1.61 (95% CI 1.26–
2.05) for antidepressant users compared to women with psychiatric
illness but no antidepressant use, versus 1.88 (1.48–2.40) compared
to women without psychiatric illness or antidepressant use
(Figure 4, Table 2). Oberlander et al [50] found an increased
risk of preterm birth for women taking antidepressant medication
compared to untreated women with a depression diagnosis (1.42,
1.17–1.72), but the association was much attenuated in a subgroup
matched on depression severity (1.12, 0.75–1.64). Wisner and
colleagues [60] found an increased risk for women on SSRI
treatment (OR=2.82), which was similar in magnitude to the
increased risk seen in women with a depression diagnosis who
were untreated (OR=2.48), both compared to untreated women
without depression. There were substantial differences, however,
between SSRI users and non-users in terms of socio-economic
status, alcohol use, and history of preterm birth, with SSRI users
having consistently worse histories in these domains. These
differences likely contributed to the equally high preterm birth
rate observed among women with untreated depression (.20%),
and were not accounted for in the analyses which only adjusted for
age and race.
A few studies indirectly addressed the issue of confounding by
depression by comparing preterm birth rates in women who
continued vs. those who discontinued their antidepressant
medication during pregnancy. Comparing women who continued
antidepressant use through the third trimester with those who
discontinued, Chambers and colleagues estimated an OR of 4.8
for fluoxetine [33]. Toh et al observed an increased risk of preterm
birth in women who continued SSRI treatment beyond the first
trimester (OR=1.27), but not in those who discontinued their
medication before the end of the first trimester (OR=1.01),
although the CI were wide and largely overlapped (Table 1) [58].
Sensitivity Analyses
Figure 5 displays the strength of the association between a
potential unmeasured confounder and the exposure (OREC) and
the outcome (RRCD) that would be required to fully explain the
observed increased rate of preterm birth associated with antide-
pressant medication use during pregnancy (depression-adjusted
OR=1.61) if in truth no such increase existed. For an unmeasured
confounder present in 25% of the population, relative risks $4
linking the hypothetical confounder to both antidepressant
medication use and preterm birth would need to be present to
fully explain the observed association, assuming 8% of pregnant
women are exposed to antidepressants [14]. For a confounder
present in just 5% of the population, relative risks .5.5 would be
needed. For an apparent association of 1.26 (lower bound of the
95% CI for the depression-adjusted OR), the required strength
would be .2.5 for an unmeasured confounder present in at most
25% of the population.
Visual inspection of the funnel plot reveals some asymmetry,
suggesting smaller studies with negative associations might be
under-represented in the literature (Figure 6). It should be noted,
however, that funnel plot asymmetry need not result from bias
[15].
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This systematic review of the literature concerning the
relationship between antidepressant use and preterm birth
identified 41 observational studies. Findings suggest the risk of
preterm birth is increased in women treated with antidepressant
medications during pregnancy, with pooled odds ratio estimates
ranging between 1.16 (95% CI 0.92–1.45) and 1.96 (95% CI 1.62–
2.38). The associations were stronger for antidepressant use later
in pregnancy. Adjusting for a diagnosis of depression in most cases
did not eliminate the effect, although the strength of the observed
associations was somewhat attenuated. Sensitivity analyses dem-
onstrated that very strong risk factors of preterm birth that are
fairly imbalanced among exposure groups and independent of the
adjusted confounders must be unmeasured and uncontrolled to
explain the observed associations. Although it would be unlikely to
miss such a strong single confounder, it is conceivable that several
weaker confounders could have acted together to account for the
apparent effect. Our findings are consistent with those from an
earlier study which evaluated the association between prenatal
antidepressant exposure and a range of adverse pregnancy and
delivery outcome [73].
Preterm birth is a major problem worldwide [74]. The rate of
antidepressant use during pregnancy has steadily increased over
time in many industrialized nations, from less than 1% of women
exposed in the early 90s to 3–6% in 2006 in Europe [10,12], and
to 7.5% in 2008 in the US [13]. It is therefore essential to
determine if antidepressant use increases the risk of preterm birth.
Studies in this area, however, are complicated due to several
issues.
First, antidepressant exposure in many pregnancies is not a ‘‘yes
or no’’ phenomenon. Many women stop antidepressants when
they discover they are pregnant, resulting in first trimester
exposure only. Others stop, but may restart the medications later
in the pregnancy. Still other patients do not take the medications
Figure 2. Study-specific and pooled odds ratio estimates for antidepressant medication during pregnancy and preterm birth.
Studies that did not adjust for other risk factors.
doi:10.1371/journal.pone.0092778.g002
Table 2. Effect of antidepressant medication use during pregnancy on preterm birth: meta-analysis results.
Level of adjustment
Timing of
exposure
Number of individual
study estimates
Summary OR
(95% CI) Heterogeneity
Qdf (P value)
I
2(95% uncertainty
interval)
(4)
Unadjusted Early
(1) 8 1.57 (1.30–1.90) 8.097 (0.324) 13.5 (0.0–56.2)
Any time 4 1.44 (1.34–1.56) 2.873 (0.411) 0.0 (0.0–84.0)
Adjusted for potential confounders
(3) Early 8 1.16 (0.92–1.45) 46.477 (,0.001) 84.9 (72.1–91.9)
Late
(2) 12 1.96 (1.62–2.38) 69.2611 (,0.001) 84.1 (73.8–90.4)
Any time 17 1.53 (1.40–1.66) 19.7216 (0.233) 18.9 (0.0–54.3)
Adjusted for psychiatric illness
Controls with psychiatric illness All combined 12 1.61 (1.26–2.05) 20.4711 (0.039) 46.3 (0.0–72.5)
Controls without psychiatric illness All combined 7 1.88 (1.48–2.40) 7.466 (0.280) 19.6 (0.0–63.2)
(1)Typically 1st trimester; some women continued during pregnancy, others discontinued.
(2)Typically 3
rd trimester.
(3)Factors varied between studies, but typically included maternal age, smoking, alcohol use, parity, and history of prematurity or miscarriage.
(4)Values of I
2 are percentages (% of variance explained). 95% uncertainty intervals are calculated as proposed by Higgins and Thompson [89].
doi:10.1371/journal.pone.0092778.t002
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issue of classifying exposure is therefore complex. Several studies,
for example, have been performed by Teratogen Information
Services (TIS). Women who called the TIS and reported that they
were taking antidepressants were classified as ‘‘exposed’’ in those
studies. The advantages of this design include the fact that
exposure is determined prior to outcome, eliminating recall bias,
and a control group is readily identifiable–women who contact the
TIS with exposure to another medication. Yet, there are also
major drawbacks to this approach. Most women who contact TIS
are concerned about the use of antidepressants during pregnancy;
therefore many of them may not continue with the medication
throughout the pregnancy. If exposure to antidepressants in the
second and third trimesters is more likely to be associated with
preterm birth (and available evidence suggests that this might be
the case) then TIS studies that classify women as exposed solely on
the basis of first trimester exposure would likely underestimate the
association between antidepressant use and preterm delivery.
Studies that rely on electronic healthcare databases, on the other
hand, contain detailed information on filled prescriptions for
antidepressant medications during the entire pregnancy. Auto-
mated pharmacy dispensing information is usually seen as the gold
standard of drug exposure compared to self-reported information
[75] or prescribing records in outpatient medical records [76].
Patient recall bias is not an issue in healthcare utilization databases
since all data recording is independent of a patient’s memory or
agreement to participate in a research study [77–80]. However,
filling a prescription does not necessarily guarantee that it was
ingested, which could result in some misclassification. Such
misclassification of exposure which is independent of the outcome
status is likely to bias results towards the null (i.e. attenuate the
association between antidepressant use and preterm birth.).
Figure 3. Study-specific and pooled odds ratio estimates for antidepressant medication during pregnancy and preterm birth.
Studies that adjusted for other risk factors.
doi:10.1371/journal.pone.0092778.g003
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underlying depression and its severity, and associated poor health
behaviors (e.g., nutrition, smoking, drug and alcohol use). More
severely depressed women may be more likely to take antidepres-
sants during pregnancy, and it has been suggested that it may be
the depression itself that is causing the preterm birth and not the
medication. Several of the studies in this systematic review made
efforts to control for maternal depression and these studies
continued to show increased rates of preterm birth in the
antidepressant exposed pregnancies. The majority of studies we
reviewed did not find increased preterm birth rates in depressed
women unexposed to medication. However, despite these studies’
attempts to control for depression, it is likely that women with a
diagnosis of depression who opt to continue treatment during
pregnancy are inherently different from women with a depression
diagnosis who discontinue treatment during pregnancy. It is
therefore questionable whether these studies completely addressed
confounding by indication severity. Nevertheless, the available
data on whether depression itself is associated with preterm birth is
inconsistent [81], and expert review panels have concluded that
there is no clear association between depression and preterm birth.
The Institute of Medicine reviewed this question and concluded
that ‘‘Overall, recent prospective studies on depression do not
suggest a strong pattern for depression as a general risk for preterm
delivery, consistent with the results of earlier studies’’ [7]. A 2009
AAP/ACOG review similarly concluded: ‘‘Available data neither
support nor refute a link between MDD [major depressive
disorder] and these outcomes [preterm delivery and gestational
age]’’ [82]. Despite the weak evidence to support the independent
association between depression and adverse pregnancy outcomes,
Figure 4. Adjusted study-specific and pooled odds ratio estimates for antidepressant medication during pregnancy and preterm
birth. Subset of studies that account for the underlying psychiatric illness.
doi:10.1371/journal.pone.0092778.g004
Figure 5. Sensitivity analysis of residual confounding (Rule-out
approach). Example for estimated OR=1.61 (depression adjusted
point estimate) and OR=1.26 (lower 95% bound of depression adjusted
estimate) for different levels of confounder prevalence (& Pc=0.05,
OR=1.61;NPc=0.25, OR=1.61; % Pc=0.05, OR=1.26; #Pc=0.25,
OR=1.26). Each line splits the area into two. The upper right area
represents all combinations of OREC and RRCD that would create
confounding by an unmeasured factor strong enough to move the
point estimate of OR to the null (OR=1) or beyond. The area to the
lower left represents all parameter combinations that would not be able
to move the estimated OR to the null.
doi:10.1371/journal.pone.0092778.g005
Figure 6. Funnel plot with pseudo 95% confidence limits.
doi:10.1371/journal.pone.0092778.g006
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investigators [83].
Some limitations of this review, resulting from limitations in the
source data, should be noted. The studies included were
heterogeneous in terms of design, size, exposure assessment,
timing and nature of the exposure, and confounding adjustment.
For example, in some studies, women classified as exposed were
only those taking medication throughout the pregnancy, and
controls were those who stopped antidepressant use before the
second trimester, while in others the ‘‘exposed’’ were patients
taking an antidepressant in the first trimester, who may have
stopped by the second trimester. We tried to address this by
presenting the results separately by level of adjustment and timing
of the exposure, but assignment of studies to these categories is
somewhat subjective, and heterogeneity within categories remains.
Although we would have liked to simultaneously investigate the
effects of some of these factors through meta-regression, this
was not feasible due to an insufficient number of studies. Given
that all but one study defined preterm birth as a dichotomous
outcome (,37 gestational weeks), we were not able to examine the
strength of the association between antidepressant medication use
and very-, moderate- and mild-preterm birth respectively.
Nevertheless, even late preterm birth is a significant contributor
to poor neonatal outcomes [3–6]. Likewise, the available evidence
did not permit evaluation of the association with specific types of
prematurity [83].
The most rigorous method for determining an association
between antidepressant medication and preterm birth would be a
randomized controlled trial, and some have argued for this [84].
Yet, numerous studies are now available that suggest antidepres-
sant use during pregnancy may be associated with spontaneous
abortion [85], birth defects [86], persistent pulmonary hyperten-
sion of the newborn [87], and newborn behavioral syndrome [88].
Whether it would be ethical to randomize depressed women to a
medication arm with these possible effects is open for debate. Since
it is unlikely a randomized trial will ever be conducted and since
causality can never be ‘proven’ in the absence of trial data, we
need to decide at what point the evidence is sufficiently strong to
warrant informing patients, providers, and the public about the
potential risks, so that they can be weighed against any expected
benefits in a given patient.
In conclusion, the findings from our review of the literature are
consistent with an association between antidepressant use during
pregnancy and preterm birth, although the possibility of residual
confounding by depression severity cannot be completely ruled out
based on the available evidence. Counseling of pregnant women
must take into consideration the clinical circumstances of a given
patient, the strength of the available evidence on the risks and
benefits (i.e., avoidance of risks associated with untreated
depression), and alternatives to medication use during pregnancy.
While our study findings cannot prove causality, they reinforce the
notion that antidepressants should not be used by pregnant
women in the absence of a clear need that cannot be met through
alternative approaches.
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